Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

University Hospital, Akershus

Status and phase: Completed; Phase 4

Conditions: Parkinson Disease

Treatments: Drug: Levodopa (drug), intraduodenal administration

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00272688

Duo-HRQoL-2

Details and patient eligibility

About

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of of idiopathic Parkinsons disease
• Motor fluctuations despite optimised per oral treatment

Exclusion criteria

• Severe dementia, confusion, psychosis or depression
• Patients with contraindications against levodopa treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)